Mean Blood PressureNCT04269980
Phentolamine Versus Magnesium Sulphate Infusion During Elective Lumbar Spine Surgery: a Randomized Double Blind Comparative Study
A study testing MAP in people with Mean Blood Pressure, run by Beni-Suef University at 1 site in Egypt.
Trial summary
The aim of this study is to evaluate the efficacy of controlled hypotensive anesthesia with phentolamine versus Magnesium sulfate in patients undergoing lumbar spine fusion surgery on blood loss, total dose of hypotensive agents and quality of surgical field. Read more about this study
- Who is it for?
- Ages 20 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Mean Blood Pressure
- What is being tested?
- MAP
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2020to 30 Sep 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- orthopedic and neurological patients undergoing posterior lumbar spine fusion
- American Society of Anesthesiologists (ASA) physical status 1 or 2,
- operation time of 3 to 5 h
- mentally competent.
Who cannot join
- operation time more than 5 h.
- allergic reaction to drugs.
- Patients with a history of liver, renal, heart and vascular failure, cardiac conduction disturbance.
- opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs and calcium channel blockers (CCB).
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Benisuef univercity
Banī Suwayf
Doaa Rashwan, MD, 01011270763, doaa_rashwan@hotmail.com
About this study
The aim of this study is to evaluate the efficacy of controlled hypotensive anesthesia with phentolamine versus Magnesium sulfate in patients undergoing lumbar spine fusion surgery on blood loss, total dose of hypotensive agents and quality of surgical field.
Read the detailed description
Patients and methods:
This study will be randomized controlled study ( RCT) and will be carried out in Beni-Suef University Hospital after the approval of institutional review board and ethical committee and obtaining a written informed consent from from ASA I and II patients undergoing elective lumbar spine surgery under general anesthesia. The primary outcome will be the achievement of controlled hypotension with MAP of 50-65 mmHg. The secondary outcomes will be blood loss, total dose of hypotensive agents and quality of surgical field.
This study will enroll 30 co-operative ASA physical status I \& II patients of both sex aged 20-60 years undergoing elective lumbar spine surgry and study period will be 6 months.
Inclusion criteria:
orthopedic and neurological patients undergoing posterior lumbar spine fusion [American Society of Anesthesiologists (ASA) physical status 1 or 2, operation time of 3 to 5 h and mentally competent.
Exclusion Criteria:
- operation time more than 5 h.
- allergic reaction to drugs.
- Patients with a history of liver, renal, heart and vascular failure, cardiac conduction disturbance.
- opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs and calcium channel blockers (CCB).
The patients will be blinded to the study drugs and will be randomly assigned into two equal groups by opaque sealed envelope as follows:
Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.
Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
Anaesthetic technique:
On arrival to the operating room, standard monitoring will be established (pulse oximetry, electrocardiography, end-tidal carbon dioxide, and noninvasive arterial blood pressure monitoring), and oxygen will be delivered via a facemask. Two intravenous cannulas will placed; one (22 gauge) in a vein on the dorsum of the hand that the examined drug will be injected in and the other (20 gauge) in the opposite hand.
All patients will receive lactated ringer's solution at approximately 3-5 ml/kg/h perioperatively. The patients will be premedicated with Midazolam 0.05 mg/kg IV 3 minutes before induction. Anesthesia will induced by injecting 2.5 mg/kg propofol, 2 μg/kg fentanyl \& 0.5 mg/kg atracurium.
The patients will be ventilated via face mask with 100 % oxygen at a rate of 4 L/min and isoflurane 1.2 %. After 3 minutes, the patients will be intubated using appropriate sized cuffed oral tube lubricated with lidocaine jelly 2 % , After induction of anesthesia, a radial arterial line from the non-dominant hand for continuous monitoring of mean arterial pressure (MAP) will be obtained.
Maintenance of anesthesia will done using isoflurane 1.2 % in 100 % O2. Muscle relaxation will be continued by atracurium 0.1 mg/kg every 20 min. All patients will be mechanically ventilated to maintain end-tidal carbon dioxide between 35-40 mmHg. For 5 minutes, no surgical interventions will be allowed in the subjects to assess target blood pressure.
The MAP will then gradually reduced in both groups to achieve and maintain the target MAP of 50-65 mmHg.
The surgical field will be evaluated by the surgeon using the 0-5 point bleeding scale (0: no bleeding, 1: low bleeding-bleeding does not require aspiration, 2: low bleeding-bleeding requires intermittent aspiration, 3: low bleeding-bleeding requires frequent aspiration, 4: moderate bleeding-bleeding becomes serious when aspirator is withdrawn from the surgical field, 5: serious bleeding-requires persistent aspiration, surgical field impossible) during the intra-operative period (13).
Patients who will develop severe hypotension (MAP <50 mmHg) will be managed by discontinuation of the hypotensive agent and reducing the concentration of isoflurane. If the MAP does not improve, 6 mg Ephedrine will be given IV \& these patients will be excluded from the study. Patient who will develop bradycardia (<50 bpm) will be managed by intravenous atropine and will be then excluded from this study.
Infusion of the hypotensive agent will be stopped 5 minutes before the anticipated end of surgery. Any residual neuromuscular block will be antagonized with neostigmine 0.04 mg/kg and atropine 0.02 mg/kg IV.
The patients will be extubated on recovery of adequate tidal volume and sufficient respiratory efforts and transferred to recovery room for observation.
Surgeon's satisfaction will be recorded using the Likert technique or scale at the end of surgery (1 = very dissatisfied to 5 = completely satisfied).
The following data will be recorded :-
- Demographic data of the patients (Age, Sex, BMI) .
- MAP, HR, ETCO2 and SPO2 were recorded immediately prior to induction of anesthesia and subsequently every 5 min till the termination of anesthesia.
- Total phentolamine and magensium doses.
- The quality of surgical field will be evaluated by surgeon using the 0-5 point bleeding scale.
- The amount of blood loss will be determined by collecting the blood and rinsed fluid from the surgical field into the suction bottle by suctioning .The nurse who will not a part of the study made visual assessment of blood soaked gauge pieces that will be consumed during surgery.
- The time needed to reach the target blood pressure.
- Duration of surgery and anesthesia. HB and HTC preoperative and intraoperative Units of blood transfused
- In the recovery room, adverse effects such as nausea, vomiting, agitation, bradycardia, coughing, shivering, reflex tachycardia and rebound hypertension will be recorded.
- Conditions
- Mean Blood Pressure
- Being tested
- MAP
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MAPOther
MAP
| Study group | Role | What they receive |
|---|---|---|
| Group (PHN) | Active comparator | Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure Receives: Other: MAP |
| Group MG | Active comparator | Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr . Receives: Other: MAP |
What is being measured
The primary outcome is the main question the study is designed to answer.
mean blood presure
Measured: intraopertaive
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2020
- Study start1 Apr 2020
- Primary completion30 Sep 2020 (estimated)
- Study completion30 Sep 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mean Blood PressureStudies of the same condition, open and under way.
- More trials run by Beni-Suef UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, doaa rashwan, Beni-Suef University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04269980
- Sponsor's protocol ID
- FMBSUREC/090222020/Ali
- Status last verified
- Jul 2020
- First submitted
- 11 Feb 2020
- Last updated
- 17 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phentolamine Versus Magnesium Sulphate Infusion During Elective Lumbar Spine Surgery: a Randomized Double Blind Comparative Study
- ClinicalTrials.gov ID
- NCT04269980
- Acronym / sponsor ID
- FMBSUREC/090222020/Ali
- Conditions
- Mean Blood Pressure
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 1 Apr 2020 (actual)
- Primary completion
- 30 Sep 2020 (estimated)
- Study completion
- 30 Sep 2020 (estimated)
- First posted
- 17 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the efficacy of controlled hypotensive anesthesia with phentolamine versus Magnesium sulfate in patients undergoing lumbar spine fusion surgery on blood loss, total dose of hypotensive agents and quality of surgical field.
Detailed description
Patients and methods:
This study will be randomized controlled study ( RCT) and will be carried out in Beni-Suef University Hospital after the approval of institutional review board and ethical committee and obtaining a written informed consent from from ASA I and II patients undergoing elective lumbar spine surgery under general anesthesia. The primary outcome will be the achievement of controlled hypotension with MAP of 50-65 mmHg. The secondary outcomes will be blood loss, total dose of hypotensive agents and quality of surgical field.
This study will enroll 30 co-operative ASA physical status I \& II patients of both sex aged 20-60 years undergoing elective lumbar spine surgry and study period will be 6 months.
Inclusion criteria:
orthopedic and neurological patients undergoing posterior lumbar spine fusion [American Society of Anesthesiologists (ASA) physical status 1 or 2, operation time of 3 to 5 h and mentally competent.
Exclusion Criteria:
- operation time more than 5 h.
- allergic reaction to drugs.
- Patients with a history of liver, renal, heart and vascular failure, cardiac conduction disturbance.
- opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs and calcium channel blockers (CCB).
The patients will be blinded to the study drugs and will be randomly assigned into two equal groups by opaque sealed envelope as follows:
Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.
Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
Anaesthetic technique:
On arrival to the operating room, standard monitoring will be established (pulse oximetry, electrocardiography, end-tidal carbon dioxide, and noninvasive arterial blood pressure monitoring), and oxygen will be delivered via a facemask. Two intravenous cannulas will placed; one (22 gauge) in a vein on the dorsum of the hand that the examined drug will be injected in and the other (20 gauge) in the opposite hand.
All patients will receive lactated ringer's solution at approximately 3-5 ml/kg/h perioperatively. The patients will be premedicated with Midazolam 0.05 mg/kg IV 3 minutes before induction. Anesthesia will induced by injecting 2.5 mg/kg propofol, 2 μg/kg fentanyl \& 0.5 mg/kg atracurium.
The patients will be ventilated via face mask with 100 % oxygen at a rate of 4 L/min and isoflurane 1.2 %. After 3 minutes, the patients will be intubated using appropriate sized cuffed oral tube lubricated with lidocaine jelly 2 % , After induction of anesthesia, a radial arterial line from the non-dominant hand for continuous monitoring of mean arterial pressure (MAP) will be obtained.
Maintenance of anesthesia will done using isoflurane 1.2 % in 100 % O2. Muscle relaxation will be continued by atracurium 0.1 mg/kg every 20 min. All patients will be mechanically ventilated to maintain end-tidal carbon dioxide between 35-40 mmHg. For 5 minutes, no surgical interventions will be allowed in the subjects to assess target blood pressure.
The MAP will then gradually reduced in both groups to achieve and maintain the target MAP of 50-65 mmHg.
The surgical field will be evaluated by the surgeon using the 0-5 point bleeding scale (0: no bleeding, 1: low bleeding-bleeding does not require aspiration, 2: low bleeding-bleeding requires intermittent aspiration, 3: low bleeding-bleeding requires frequent aspiration, 4: moderate bleeding-bleeding becomes serious when aspirator is withdrawn from the surgical field, 5: serious bleeding-requires persistent aspiration, surgical field impossible) during the intra-operative period (13).
Patients who will develop severe hypotension (MAP <50 mmHg) will be managed by discontinuation of the hypotensive agent and reducing the concentration of isoflurane. If the MAP does not improve, 6 mg Ephedrine will be given IV \& these patients will be excluded from the study. Patient who will develop bradycardia (<50 bpm) will be managed by intravenous atropine and will be then excluded from this study.
Infusion of the hypotensive agent will be stopped 5 minutes before the anticipated end of surgery. Any residual neuromuscular block will be antagonized with neostigmine 0.04 mg/kg and atropine 0.02 mg/kg IV.
The patients will be extubated on recovery of adequate tidal volume and sufficient respiratory efforts and transferred to recovery room for observation.
Surgeon's satisfaction will be recorded using the Likert technique or scale at the end of surgery (1 = very dissatisfied to 5 = completely satisfied).
The following data will be recorded :-
- Demographic data of the patients (Age, Sex, BMI) .
- MAP, HR, ETCO2 and SPO2 were recorded immediately prior to induction of anesthesia and subsequently every 5 min till the termination of anesthesia.
- Total phentolamine and magensium doses.
- The quality of surgical field will be evaluated by surgeon using the 0-5 point bleeding scale.
- The amount of blood loss will be determined by collecting the blood and rinsed fluid from the surgical field into the suction bottle by suctioning .The nurse who will not a part of the study made visual assessment of blood soaked gauge pieces that will be consumed during surgery.
- The time needed to reach the target blood pressure.
- Duration of surgery and anesthesia. HB and HTC preoperative and intraoperative Units of blood transfused
- In the recovery room, adverse effects such as nausea, vomiting, agitation, bradycardia, coughing, shivering, reflex tachycardia and rebound hypertension will be recorded.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group (PHN) | Active comparator | Other: MAPGroup (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure |
| Group MG | Active comparator | Other: MAPGroup MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr . |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- orthopedic and neurological patients undergoing posterior lumbar spine fusion
- American Society of Anesthesiologists (ASA) physical status 1 or 2,
- operation time of 3 to 5 h
- mentally competent.
Key exclusion criteria (4 listed)
- operation time more than 5 h.
- allergic reaction to drugs.
- Patients with a history of liver, renal, heart and vascular failure, cardiac conduction disturbance.
- opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs and calcium channel blockers (CCB).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MAPMAP | Other | Group (PHN), Group MG |
Primary outcome
mean blood presure
Time frame: intraopertaive
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2020.
- Individual participant dataSharing planned: Undecided
Related trials for Mean Blood Pressure
RecruitingPhase 4
Remimazolam Versus Propofol for Maintenance of Anaesthesia During Major Hepatectomy Under Low Central Venous Pressure
Intraoperative Hypotension, Hepatectomy
Not yet recruitingObservational study
Cumulative Intra-Abdominal Pressure Burden and Acute Kidney Injury After Emergency Abdominal Surgery
Acute Kidney Injury, Intra-Abdominal Hypertension
Not yet recruiting
Perfusion Efficiency-Guided MAP De-escalation in Elderly Septic Shock
Sepsis
Recruiting
Effects of Different MAP Targets on Ocular Perfusion and Optic Nerve Microvasculature During Rhinoplasty
Controlled Hypotension for Nasal Surgeries
Recruiting
Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock
Cardiogenic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MAP in people with Mean Blood Pressure, run by Beni-Suef University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mean blood presure (time frame: intraopertaive). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2020.